AC
BLCM

Ascend Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Ascend Capital’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,099
Closed -$2.63M – 244
2018
Q1 		$2.63M Buy
+40,099
New +$3.03M 0.11% 153

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital's BLCM Position: Q2 2018 in Review

Ascend Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2018, closing a stake of 40,099 shares — an estimated $2.63M sold.

Ascend Capital first reported a position in BLCM in Q1 2018 and held it in 1 quarter. The position peaked at $2.63M in Q1 2018. 96 funds tracked by Wall St. Rank hold BLCM as of Q2 2018.

  • Ascend Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 40,099 Bellicum Pharmaceuticals, Inc. shares in Q2 2018, an estimated $2.63M.
  • Ascend Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Ascend Capital's Bellicum Pharmaceuticals, Inc. position peaked at $2.63M in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.